2018
DOI: 10.1016/j.jval.2018.07.352
|View full text |Cite
|
Sign up to set email alerts
|

Evolution of Hta System in Japan: Progress and Conservatism

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2020
2020
2020
2020

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…40 In April 2018, cost-effectiveness results were used to reduce the price of 2 drugs selected for the HTA pilot program, nivolumab and adotrastuzumab emtansine. 41 As the new HTA processes from the pilot program are fully implemented, cooperation between the government and pharmaceutical manufacturers will be needed to reach pricing agreements. Japan's tightly regulated healthcare system has led the pharmaceutical industry to only sparingly, if ever, generate and use pharmacoeconomics data.…”
Section: Future Challengesmentioning
confidence: 99%
“…40 In April 2018, cost-effectiveness results were used to reduce the price of 2 drugs selected for the HTA pilot program, nivolumab and adotrastuzumab emtansine. 41 As the new HTA processes from the pilot program are fully implemented, cooperation between the government and pharmaceutical manufacturers will be needed to reach pricing agreements. Japan's tightly regulated healthcare system has led the pharmaceutical industry to only sparingly, if ever, generate and use pharmacoeconomics data.…”
Section: Future Challengesmentioning
confidence: 99%